obesity

Boehringer Ingelheim, Gubra to validate new Peptides for obesity
Boehringer Ingelheim, Gubra to validate new Peptides for obesity
Pharmaceutical Business Review
Boehringer Ingelheim
Gubra
peptides
obesity
Flag link:
Novo Nordisk's blockbuster diabetes drug blows the doors off in obesity, proving highly effective in driving weight loss
Novo Nordisk's blockbuster diabetes drug blows the doors off in obesity, proving highly effective in driving weight loss
Endpoints
Novo Nordisk
semaglutide
obesity
Flag link:
Looking to win over some skeptical analysts, Rhythm beats the drum on interim data in PhII basket study for additional indications
Looking to win over some skeptical analysts, Rhythm beats the drum on interim data in PhII basket study for additional indications
Endpoints
Rhythm Pharmaceuticals
clinical trials
setmelanotide
obesity
Flag link:
Rhythm Pharma knocked off stride as mixed PhIII obesity data for its sole big drug look ‘meh’ to many
Rhythm Pharma knocked off stride as mixed PhIII obesity data for its sole big drug look ‘meh’ to many
Endpoints
Rhythm Pharmaceuticals
setmelanotide
obesity
clinical trials
Flag link:
FDA gives Rhythm the green light for setmelanotide, a drug aimed at reducing obesity in certain genetic disorders
FDA gives Rhythm the green light for setmelanotide, a drug aimed at reducing obesity in certain genetic disorders
Endpoints
Rhythm Pharmaceuticals
setmelanotide
obesity
FDA
Flag link:
Novo adds weight to its obesity goals
Novo adds weight to its obesity goals
EP Vantage
Novo Nordisk
semaglutide
obesity
Flag link:
Highlights: 2020 Cardiometabolic Health Congress West Live Online
Highlights: 2020 Cardiometabolic Health Congress West Live Online
CP WIre
cardiometabolic health
cardiovascular disease
obesity
Flag link:
Novo Nordisk axes experimental obesity drugs after success with later-stage meds
Novo Nordisk axes experimental obesity drugs after success with later-stage meds
Fierce Biotech
Novo Nordisk
obesity
semaglutide
Flag link:
Heart Drugs May Influence Gut Microbiome In Obese People, Says New Study
Heart Drugs May Influence Gut Microbiome In Obese People, Says New Study
Forbes
microbiome
obesity
statins
Flag link:
Will Novo’s big thinking in obesity pay off?
Will Novo’s big thinking in obesity pay off?
EP Vantage
Novo Nordisk
obesity
Ozempic
AM833
clinical trials
Flag link:
Insights into how Novo Nordisk's Saxenda cuts food cravings may inspire new obesity drugs
Insights into how Novo Nordisk's Saxenda cuts food cravings may inspire new obesity drugs
Fierce Biotech
Novo Nordisk
Saxenda
obesity
food cravings
Flag link:
Kintai’s obesity drug that works via the gut microbiome moves closer to the clinic
Kintai’s obesity drug that works via the gut microbiome moves closer to the clinic
Fierce Biotech
microbiome
obesity
Kintai Therapeutics
Flag link:
Gene therapy to fend off aging? Buzzy Harvard startup Rejuvenate Bio says it works in mice
Gene therapy to fend off aging? Buzzy Harvard startup Rejuvenate Bio says it works in mice
Fierce Biotech
gene therapy
age-related disease
type 2 diabetes
obesity
heart failure
kidney failure
Rejuvenate Bio
Flag link:
Highlights: 2019 Cardiometabolic Health Congress, Chicago IL
Highlights: 2019 Cardiometabolic Health Congress, Chicago IL
CP Wire
cardiometabolic health
GLP-1 agonist
diabetes
lipids
hypertension
chronic kidney disease
heart failure
obesity
Flag link:
Highlights: 2019 Cardiometabolic Health Congress, Chicago IL
cardiometabolic health
GLP-1 agonist
diabetes
lipids
hypertension
chronic kidney disease
heart failure
obesity
Flag link:
Novo Nordisk announces obesity digital health tie-up with Noom
Novo Nordisk announces obesity digital health tie-up with Noom
Pharmaforum
Novo Nordisk
Noom
digital health
obesity
Flag link:
J&J dumps Hanmi obesity drug following midphase trials
J&J dumps Hanmi obesity drug following midphase trials
Fierce Biotech
JNJ
HM12525A
obesity
Hanmi Pharmaceutical
Flag link:
Boehringer Ingelheim, Gubra to develop anti-obesity peptide poly-agonists
Boehringer Ingelheim, Gubra to develop anti-obesity peptide poly-agonists
Pharmaceutical Business Review
obesity
peptide poly-agonists
Boehringer Ingelheim
Gubra
Flag link:
Even as obesity rates climb, new diabetes cases fall
Even as obesity rates climb, new diabetes cases fall
Stat
diabetes
obesity
Flag link:
FDA approves PureTech’s obesity device Plenity
FDA approves PureTech’s obesity device Plenity
Pharmaforum
FDA
PureTech Health
devices
obesity
Plenity
Flag link:

Pages